Beam Therapeutics rises on early-stage trial results for gene editing therapy

Beam Therapeutics

10/03/2025 12:07

** Biotech firm Beam Therapeutics' BEAM.O shares rise 9.7% to $31.24 premarket

** BEAM says its experimental gene-editing therapy, BEAM-302, surpassed theoretical threshold for efficacy with the third dose level of 60 mg of the therapy

** Three patients received the 60 mg dose in an early-stage study to treat Alpha-1 antitrypsin deficiency (AATD)

** AATD is a genetic disorder that occurs when the body doesn't produce enough of the AAT protein which protects lungs and liver

** There is a clear path forward for BEAM-302 - brokerage BMO Capital Markets

** Co plans to continue testing higher doses in the ongoing study, expects to report further data in H2 2025

** BEAM has fallen 23% in the past 12 months

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))